<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/229D0677-C57B-4379-9DCB-9213DDE29E53"><gtr:id>229D0677-C57B-4379-9DCB-9213DDE29E53</gtr:id><gtr:name>Global Medical Excellence Cluster (GMEC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/229D0677-C57B-4379-9DCB-9213DDE29E53"><gtr:id>229D0677-C57B-4379-9DCB-9213DDE29E53</gtr:id><gtr:name>Global Medical Excellence Cluster (GMEC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B3E2E4ED-EC4F-429B-8C53-103A24E00553"><gtr:id>B3E2E4ED-EC4F-429B-8C53-103A24E00553</gtr:id><gtr:firstName>Jill</gtr:firstName><gtr:surname>Belch</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F39F5648-4269-4976-8E40-6C8DDC92BDC8"><gtr:id>F39F5648-4269-4976-8E40-6C8DDC92BDC8</gtr:id><gtr:firstName>Shirley</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>McEwan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5616E0EF-6C13-4DEC-A430-FD94E45534C7"><gtr:id>5616E0EF-6C13-4DEC-A430-FD94E45534C7</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Prescott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9534799"><gtr:id>FD52B5F1-B4C7-4EF0-BA3F-55973040E8B0</gtr:id><gtr:title>The Prevention of Progression of Asymptomatic Diabetic Arterial Disease (POPADAD) Study [extension to December 2006]</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9534799</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1997-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2094099</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Global Medical Excellence Cluster (GMEC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ATT Bleeding meta analysis</gtr:description><gtr:id>7AFF155F-A982-4DED-952A-3010D460B693</gtr:id><gtr:impact>A paper has been written and submitted for publication</gtr:impact><gtr:outcomeId>ftzVtCgkZVD-1</gtr:outcomeId><gtr:partnerContribution>Resulted in a meta analysis on aspirin and bleeding which is about to be published</gtr:partnerContribution><gtr:piContribution>Discussions with authors (Baigent and Bhala) and provision of data and analyses from the POPADAD study</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Global Medical Excellence Cluster (GMEC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Aspirin Cancer meta analyses</gtr:description><gtr:id>21C64524-31F2-497F-9168-F0C6470E7EE9</gtr:id><gtr:impact>Lancet. 2011 Jan 1;377(9759):31-41. Epub 2010 Dec 6.
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW

Plus further paper in press</gtr:impact><gtr:outcomeId>Ckpu1j7uofL-1</gtr:outcomeId><gtr:partnerContribution>Opened up the research from purely cardiovascular to include Cancer</gtr:partnerContribution><gtr:piContribution>Worked with Peter Rothwell to provide POPADAD data for a meta analysis looking at aspirin as a preventive medication for cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>TV</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1A6832AE-3085-471E-9B71-5557A77A7E7A</gtr:id><gtr:impact>A number of new-night style interviews were carried out for TV over 08/09/10 within the UK.

Patients much more aware of aspirin's role in health</gtr:impact><gtr:outcomeId>eE21XjwP3aR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient self help groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0A43B1BB-FDC2-40F7-9B8D-6EED8D985E10</gtr:id><gtr:impact>Talking to varios Diabetes self health groups

To better understand the role of aspirin in diabetes</gtr:impact><gtr:outcomeId>DXS2sMU5wwk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lay lectures, newspaper reports, TV, radio</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>25ADCF40-726F-41BF-B35A-E6B260ECA88E</gtr:id><gtr:impact>Newspaper interviews, radio slots, TV appearances, editing lay articles for magazines, speaking at lay lectures, speaking to Diabetes groups

New York Times headline. Over 500 letters from patients.</gtr:impact><gtr:outcomeId>7506179415D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5A9F3E9D-5E8F-45B7-A261-E03AEDCA9AF0</gtr:id><gtr:impact>Many radio interviews, world wide in 2008 and 2009. Countires included UK, Ireland, New Zealand, Australia, USA and Canada.

Patients attending GPs worlwide to ask if need aspirin</gtr:impact><gtr:outcomeId>sN9u7CAxiXu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>clinical trial</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>EBE417D7-D7A8-4EF4-9112-C1BED2F41A05</gtr:id><gtr:outcomeId>LMCAKKpix2h0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Heart Foundation</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>31909054-823C-49B6-BE28-5DD05659E31C</gtr:id><gtr:outcomeId>f2KAg73KQE80</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:guidelineTitle>SIGN 116: Management of Diabetes</gtr:guidelineTitle><gtr:id>B673D5B6-3189-4D1D-B705-DDDEE83C0B17</gtr:id><gtr:impact>Prevention of bleeding without therapeutic benefit</gtr:impact><gtr:outcomeId>bDd4LGpzx7K</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.sign.ac.uk/guidelines/fulltext/116/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Editorial</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>56B30AEC-02FC-4D48-9075-94FA7DCF94A0</gtr:id><gtr:impact>PMID: 19771482</gtr:impact><gtr:outcomeId>SMMT2fDvrjG</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19771482</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation and change of practice</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Standard of Medical care in Diabetes</gtr:guidelineTitle><gtr:id>6F32F053-B694-408B-9789-AED9EDB61B2A</gtr:id><gtr:impact>American Diabetes Association
Standards of Medical Care in Diabetes-2010 
Diabetes Care January 2010 33:S11-S61; doi:10.2337/dc10-S011 
Limited aspirin prescribing for primary prevention</gtr:impact><gtr:outcomeId>GFtZPXKhDdi</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://care.diabetesjournals.org/content/33/Supplement_1/S13</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Editorial</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>71F79109-4F03-4AF1-8F0F-15406A07257C</gtr:id><gtr:impact>PMID: 19153560</gtr:impact><gtr:outcomeId>WmnWSVmgCst</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19153560</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Quite a few Editorials written</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2D0F8BD9-9B34-42F5-AF67-8CAD264D615F</gtr:id><gtr:impact>Aspirin not proven to benefit patients with Diabetes and no evidence of CVD</gtr:impact><gtr:outcomeId>8ADF33CC912</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Editorial</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>822635C2-08AB-4612-921B-4ED94F7B960B</gtr:id><gtr:impact>PMID: 19019865</gtr:impact><gtr:outcomeId>o5dEg6xDmr5</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19019865</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E2BCF9BF-F935-4F41-B7F8-71009DA934AA</gtr:id><gtr:title>[Effects of low-dose aspirin on primary prevention of cardiovascular events: a systematic review].</gtr:title><gtr:parentPublicationTitle>Zhonghua xin xue guan bing za zhi</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/517e407bcd7515853be9043c188f1a93"><gtr:id>517e407bcd7515853be9043c188f1a93</gtr:id><gtr:otherNames>Tang HQ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0253-3758</gtr:issn><gtr:outcomeId>ATfwP4soPTD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDCC3BCE-FDDD-40E3-9835-2E1C9AD0B106</gtr:id><gtr:title>The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d45fef1e36f2226c802decf0566fbfc3"><gtr:id>d45fef1e36f2226c802decf0566fbfc3</gtr:id><gtr:otherNames>Belch J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>E0866AD98A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>236C7B38-2089-4DD0-855A-418C3C2F4B2C</gtr:id><gtr:title>Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ecc6eb359e37f1f832c733561cbe61"><gtr:id>56ecc6eb359e37f1f832c733561cbe61</gtr:id><gtr:otherNames>Rothwell PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>NHKhPYqjh74</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46F2AAFF-4647-4E1A-B877-5A9B1E9F78F4</gtr:id><gtr:title>Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.</gtr:title><gtr:parentPublicationTitle>The American journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4858a807aa3c217228d6977497e4f3b5"><gtr:id>4858a807aa3c217228d6977497e4f3b5</gtr:id><gtr:otherNames>Bartolucci AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9149</gtr:issn><gtr:outcomeId>56cc3b6c0c0076.54260758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F335DDE-1621-4675-83BC-061FC8EF5208</gtr:id><gtr:title>Effect of aspirin on mortality in the primary prevention of cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>The American journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64734f0fc6b5c3f2167d92b16778235d"><gtr:id>64734f0fc6b5c3f2167d92b16778235d</gtr:id><gtr:otherNames>Raju N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9343</gtr:issn><gtr:outcomeId>56cc3ca1a06313.89917919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BA0BEE8-CDFA-4409-AE54-8C41EA969ED5</gtr:id><gtr:title>Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/422e300a7c5463cf3187c6b8452775db"><gtr:id>422e300a7c5463cf3187c6b8452775db</gtr:id><gtr:otherNames>Antithrombotic Trialists' (ATT) Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56cc37b79c9ac3.84556956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFDE3DFA-D197-46B7-9C81-2249C43ADB13</gtr:id><gtr:title>Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.</gtr:title><gtr:parentPublicationTitle>Archives of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e39aa821ad0c479c445b256c6625a33"><gtr:id>9e39aa821ad0c479c445b256c6625a33</gtr:id><gtr:otherNames>Seshasai SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn><gtr:outcomeId>56cc3d8da817b6.60605051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8682873-89F7-4D35-8702-83ED3F3B86E8</gtr:id><gtr:title>Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ecc6eb359e37f1f832c733561cbe61"><gtr:id>56ecc6eb359e37f1f832c733561cbe61</gtr:id><gtr:otherNames>Rothwell PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>tay4dZS6yEQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2349A96E-E976-4811-A593-57A7B33E63E6</gtr:id><gtr:title>Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f059fd8105f1cbbdab60b2c63ebbed2"><gtr:id>0f059fd8105f1cbbdab60b2c63ebbed2</gtr:id><gtr:otherNames>Soejima H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>dk2QQ8KmwxM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DEABF3C-5D04-4275-9551-BE0FC30956F3</gtr:id><gtr:title>Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ecc6eb359e37f1f832c733561cbe61"><gtr:id>56ecc6eb359e37f1f832c733561cbe61</gtr:id><gtr:otherNames>Rothwell PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>jrgw8R8mkH7</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9534799</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>